Public vaccine manufacturing capacity in the Latin American and Caribbean region: current status and perspectives [0.03%]
拉丁美洲和加勒比地区公共新冠疫苗生产产能现状及展望
Maria de los Angeles Cortes,Daniel Cardoso,James Fitzgerald et al.
Maria de los Angeles Cortes et al.
The vaccine global market is currently growing at a rate of 16.52%. Nowadays the vaccine manufacturing industry is limited in the sense that not all vaccine manufacturers have the capacity to execute all the steps necessary to produce a suc...
Human blood-derived fibrin releasates: composition and use for the culture of cell lines and human primary cells [0.03%]
人血源性纤维蛋白释放液：组成及用于细胞系和原代人类细胞培养的方法
Thierry Burnouf,Chang-Yu Lee,Chin-Wan Luo et al.
Thierry Burnouf et al.
We have evaluated the capacity of two human blood fractions to substitute for FBS as growth medium supplement for human and animal cell cultures. Non-anticoagulated blood from volunteer donors (N = 13) was centrifuged to isolate a supernata...
Real time PCR: a rapid tool for potency estimation of live attenuated camelpox and buffalopox vaccines [0.03%]
实时荧光定量PCR技术在快速评定牛痘疫苗滴度中的应用研究
M Prabhu,M S Siva Sankar,V Bhanuprakash et al.
M Prabhu et al.
In the present study, SYBR Green and TaqMan real time PCRs (rt-PCR) based on the C18L gene (encodes ankyrin repeat protein) of camelpox (CMLV) and buffalopox viruses (BPXV) were, respectively employed for potency evaluation of live attenuat...
Evaluation of a robotic system for the recovery of peripheral blood mononuclear cells [0.03%]
评估用于外周血单个核细胞回收的机器人系统
Adrian McQuillan,Silvia Dotti,Antonio Cristiano et al.
Adrian McQuillan et al.
Investigations into immune responses are often based upon recovery of peripheral blood mononuclear cells (PBMC). To this purpose, the recovery of PBMC by gradient centrifugation is labour-intensive and requires a reasonable level of skill b...
Development of an antibody ELISA for potency testing of furunculosis (Aeromonas salmonicida subsp salmonicida) vaccines in Atlantic salmon (Salmo salar L) [0.03%]
大麻哈鱼（Salmo salar L）创诊治疫苗效力试验的抗体检测试剂条研究开发
Anne Berit Romstad,Liv Jorun Reitan,Paul Midtlyng et al.
Anne Berit Romstad et al.
The study was conducted in Atlantic salmon to establish the initial and basic scientific documentation for an alternative batch potency test for salmon furuculosis vaccines. We assessed the antibody response development for Aeromonas salmon...
Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products [0.03%]
牛血清和猪胰蛋白酶中可能污染的牛源和猪源病毒具有感染人的潜力及其风险评估研究进展综述
Carol Marcus-Sekura,James C Richardson,Rebecca K Harston et al.
Carol Marcus-Sekura et al.
Current U.S. requirements for testing cell substrates used in production of human biological products for contamination with bovine and porcine viruses are U.S. Department of Agriculture (USDA) 9CFR tests for bovine serum or porcine trypsin...
Specificity and detection limit of a dermal temperature histamine sensitization test for absence of residual pertussis toxin in vaccines [0.03%]
用于疫苗中百日咳毒素残留阴性的皮肤温度组胺敏感性试验的特异性和检出限
Sten E Jensen,Kristin E Engelhart Illigen,Jens Henrik Badsberg et al.
Sten E Jensen et al.
Currently, an assay based on fatal sensitization of mice to histamine challenge is widely used for testing absence of residual pertussis toxin in acellular pertussis containing vaccines. For replacement of this lethal end-point assay, an al...
A practical validation approach for virus titer testing of avian infectious bursal disease live vaccine according to current regulatory guidelines [0.03%]
符合现行监管指南的鸡传染性法氏囊病活疫苗滴度检测实践验证方法
Mirta Weber Sušanj,Miljenko Košiček,Ela Kosor Krnić et al.
Mirta Weber Sušanj et al.
The method for virus titer determination of avian infectious bursal disease (IBD) live vaccine, developed long before regulatory validation guidelines is a cell culture based biological assay intended for use in vaccine release testing. The...
Sunit Maity,Rajesh Ullanat,Subhra Lahiri et al.
Sunit Maity et al.
Etanercept is a soluble tumor necrosis factor (TNF) receptor originally approved for treatment of moderate-to-severe rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriatic arthritis. We have developed a non-innovator version of ...